We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novus Acquisition and Development Corporation (PK) | USOTC:NDEV | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.052 | 0.042 | 0.068 | 0.00 | 21:05:44 |
From Feb 2020 to Feb 2025
MIAMI, FL--(Marketwired - Mar 18, 2014) - Novus Acquisition & Development Corp (OTC Pink: NDEV) (PINKSHEETS: NDEV) has engaged Kingery & Crouse CPS as Novus' PCAOB auditor. The reports that Kingery & Crouse will generate will give full disclosure and transparency to Novus' financial condition. Our selection of Kingery & Crouse CPA's as it states on their website "a full spectrum of SEC auditing" as well at times they will assist Novus to register their common shares and/or comply with SEC rules and reporting requirements; elevating Novus to the status of a fully reporting company.
The selection of Kingery & Crouse CPA's is their industry expertise in Healthcare, 10-Q/10-K preparation and Consulting, Sarbanes-Oxley Advisory and Compliance. The information that they will disseminate will be financial statements that is intended for the use of the Board of Directors, stockholders and management. We at Novus welcome their professional expertise and guidance as we progress in our business model.
To learn more about Kingery & Crouse CPA's please visit their website; http://www.tampacpa.com/
About Novus Novus is comprised of seasoned Wall Street veterans that have focused its business model in the cannabis industry. Management and its proposed future Board of Directors areas of expertise will diversify in Healthcare, Physicians Education, Pharma R&D, Compliance and Business Development. NDEV will work as an outside developer and since it not Federally approved it will not cultivate, handle, transport grow, extract, dispense put up for sale, put on the market, vend, deliver, supply, circulate, trade, cannabis or any substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future and will continue to follow state and federal laws.
For investor Relations contact: Bridgewater Communications Group Main Tel: (855) 4-BCG-INFO / (855) 422-4463 Email: info@bcginfo.com Contact Novus Gary F. Labrozzi CEO 305-467-6699 www.ndev.biz
1 Year Novus Acquisition and De... (PK) Chart |
1 Month Novus Acquisition and De... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
